Lawrenceville, NJ, USA—February 5, 2019—ISPOR—the professional society for health economics and outcomes research—announced a new regional conference, ISPOR Warsaw 2019, scheduled for 27-28 March 2019 in Warsaw, Poland. The conference will center on health economics and outcomes research (HEOR) issues in Central and Eastern Europe with the theme, “Navigating Joint Health Technology Assessment, Procurement, and Fair Pricing: Evidence-Based Insights and Practical Recommendations.” The conference will bring together regional and international experts and stakeholders in HEOR to share innovative research methods and health policy developments.

The first day of the conference, Wednesday, 27 March, will feature ISPOR regional group meetings, a number of sponsored educational symposia, and an evening welcome reception for delegates. The second and final day of the conference—Thursday, 28 March—will feature 4 sessions including:

Aligning Evidence Requirements for Drug Authorization and Coverage: Central and Eastern European Countries Insights

  • Francis Arickx, MSc; Head, Directorate Pharmaceutical Policy, National Institute for Health and Disability Insurance; Belgium
  • Chantal Bélorgey, MD; Director of Medical, Economic, and Public Health Assessment, French National Authority for Health; France (invited)
  • Finn Børlum Kristensen, MD, PhD; Professor in Health Services Research and HTA at Department of Public Health Research Unit of User Perspectives, University of Southern Denmark; Denmark
  • Grzegorz Cessak, PhD; President, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Poland (invited)
  • Pero Draganic, MD, PhD; Principal Advisor for Distribution of Medicines and Pharmacoeconomics, Croatian Agency for Medicinal Products and Medical Devices, HALMED; Croatia
  • Tomáš Tesař, PharmD, PhD, MBA; Reimbursement Committee Member, Union Health Insurance Fund; Slovakia
  • Roman Topór-Mądry, MD, PhD; President, Agency for Health Technology Assessment and Tariff System; Poland (invited) 

Health Data, Health Data, and More Health Data: From Quantity to Quality Through Cooperation

  • Alexander Berler; Director Consulting Services, Gnomon Informatics SA, Chair, HL7 Hellas; Greece
  • Janusz Cieszynski; Deputy Minister of Health for Digitalization of the Medical Sector, Ministry of Health; Poland (invited)
  • Wim Goettsch, PhD; Associate Professor of Health Technology Assessment, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University; The Netherlands
  • Katarzyna Kolasa, PhD; Head of Department of Health Economics and Healthcare Management, Kozminski University; Poland
  • Guenka Petrova, MPharm, MEcon, PhD, DSc; Professor, Department of Social Pharmacy, Medical University of Sofia; Bulgaria
  • Jose Valverde Albacete, MD; Policy and Programme Officer/ Research Coordination, Directorate-General Communications Networks, Content and Technology, European Commission 

Medical Device Assessment and Procurement: Fair and Efficient Access in Countries with Limited Health Budgets

  • Richard Charter, MSc; Market Access and Value Based Healthcare Lead, Medication Delivery Systems–Europe; Switzerland
  • Rok Hren, MSc, PhD; Assistant Professor, University of Ljubljana; Slovenia
  • Ernesto Nogueira, MBA; Managing Director, ValueConnected; The Netherlands
  • Bence Takács, PhD; Health Economist, Division for Health Technology Assessment, Directorate General for Medicine Authorisation and Methodology, National Institute of Pharmacy and Nutrition; Hungary
  • Claudia Wild, DPhil; Director; Ludwig Boltzmann Institute for Health Technology Assessment; Austria 

How Far We Can Go? Finding a Common Way in Clinical Evaluation, Data Generation, and Joint Procurement and Pricing Negotiations

  • Neringa Bernotiene, MD, MSc; Deputy Director, National Health Insurance Fund; Lithuania (invited)
  • Marcin Czech, PhD, MD, MBA; former Deputy Minister of Health and Undersecretary of State; Poland
  • Iga Lipska; Hospital-Based Health Technology Assessment Project Leader, National Health Fund; Poland
  • Stanimir Hasardzhiev, MD; Secretary-General, Patient Access Partnership; Board Member, European Patients’ Forum; Secretary-General, CEE4Health Chairperson, National Patients’ Organisation; Bulgaria
  • Beatrix Horvath, MD; Director, Drug Policy Department, Ministry of Health; Hungary (invited)
  • Joanna Lis, MSc, MBA, PhD; Associate Professor, Department of Pharmacoeconomics, Medical University of Warsaw; Poland
  • Andrzej Rys, MD; Director, Health Systems, Medical Products and Innovation, DG SANTE, European Commission 

ISPOR is recognized globally as the leading professional society for HEOR and its role in improving healthcare decisions. ISPOR Warsaw 2019 will draw hundreds of healthcare stakeholders with an interest in HEOR, including policy makers from health ministries and government officials, health technology assessment bodies, international organizations, global thought leaders, researchers and academicians, public and private payers, the life sciences industry, healthcare providers, and patient engagement organizations.

Additional information on the conference can be found here: Conference Information | Registration | Exhibitor/Sponsorship and Symposia Opportunities | Press 

###

 

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn:www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/user/ispororg/videos | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg

Meeting Link: ISPOR Warsaw 2019